6.77

2.73% 0.18

After Hours: 6.77

Eupraxia Pharmaceuticals Inc (EPRX)

Overview News Price History Financials Discussions Forecast

Eupraxia Pharmaceuticals Inc stock is traded at $6.77, with a volume of 593.05K. It is up +2.73% in the last 24 hours and down -16.52% over the past month. Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.

Previous Close:

$6.59

Open:

$6.6

24h Volume:

593.05K

Relative Volume:

0.58

Market Cap:

$447.32M

Revenue:

Net Income/Loss:

$-44.47M

P/E Ratio:

-6.6496

EPS:

-1.0181

Net Cash Flow:

$-33.50M

1W Performance:

-10.57%

1M Performance:

-16.52%

6M Performance:

-8.51%

1Y Performance:

+14.55%

1-Day Range:

$6.49

$6.82

1-Week Range:

$6.42

$7.70

52-Week Range:

$5.25

$9.32

Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile

Name

Eupraxia Pharmaceuticals Inc

Sector

Healthcare (1051)

Industry

Biotechnology (593)

Phone

Address

Employee

Twitter

Next Earnings Date

2026-11-03

Latest SEC Filings

EPRX's Discussions on Twitter

Compare EPRX vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
EPRX Eupraxia Pharmaceuticals Inc	6.77	447.32M	0	-44.47M	-33.50M	-1.0181
VRTX Vertex Pharmaceuticals Inc	508.75	128.95B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	236.50	94.42B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	796.34	81.99B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	846.27	53.22B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	374.08	42.32B	5.76B	514.49M	1.10B	4.4813

Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-24-26	Initiated	Wedbush	Outperform
Jun-26-26	Initiated	Oppenheimer	Outperform
May-21-26	Initiated	Stifel	Buy
Mar-23-26	Initiated	William Blair	Outperform
Jul-24-25	Initiated	Cantor Fitzgerald	Overweight
Jun-26-25	Initiated	H.C. Wainwright	Buy
Jun-16-25	Initiated	Canaccord Genuity	Speculative Buy
Feb-21-25	Initiated	Craig Hallum	Buy
Nov-14-24	Initiated	Rodman & Renshaw	Buy

View All

Eupraxia Pharmaceuticals Inc Stock (EPRX) Latest News

Oct 09, 2026

Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences - GlobeNewswire Inc.

Oct 09, 2026

Sep 30, 2026

Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis - GlobeNewswire Inc.

Sep 30, 2026

Sep 22, 2026

Wall Street Analysts See a 145.35% Upside in Eupraxia Pharmaceuticals Inc. (EPRX): Can the Stock Really Move This High? - Eastern Progress

Sep 22, 2026

Sep 14, 2026

Eupraxia Pharmaceuticals Inc. (TSX:EPRX) Rises 5.51% as Clinical Momentum and Nasdaq Upgrade Support Investor Sentiment - kalkine.ca

Sep 14, 2026

Sep 12, 2026

Eupraxia Pharma (EPRX): When Painful Swallowing Nearly Disappeared, Investors Took Notice - Yahoo Finance

Sep 12, 2026

Sep 11, 2026

EPRX: Innovative annual therapy for EoE shows rapid, durable efficacy and strong commercial prospects - TradingView

Sep 11, 2026

Sep 09, 2026

Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) Stock Price Today: $8.25 - Gotrade

Sep 09, 2026

Sep 08, 2026

Why Eupraxia Pharmaceuticals Inc stock is skyrocketing today - Wealth Awesome

Sep 08, 2026

Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences - Investing News Network

Sep 08, 2026

Eupraxia Pharmaceuticals Moves Up to Nasdaq Global Select Market and Ramps Investor Outreach - TipRanks

Sep 08, 2026

Why Did Eupraxia Pharmaceuticals (TSX:EPRX) Surge 12.36% on 4 September 2026? - kalkine.ca

Sep 08, 2026

Pharma Eupraxia (Nasdaq: EPRX) moves to Nasdaq's top tier - Stock Titan

Sep 08, 2026

No shareholder action is needed as Eupraxia shares move to Nasdaq’s highest tier. - Stock Titan

Sep 08, 2026

Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq - GlobeNewswire

Sep 08, 2026

Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences - finance.yahoo.com

Sep 08, 2026

Sep 07, 2026